Symbols / CRDF $2.01 -0.50%
CRDF Chart
About
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 137.41M |
| Enterprise Value | 79.94M | Income | -45.88M | Sales | 593.00K |
| Book/sh | 0.66 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -2.87 | PEG | — |
| P/S | 231.73 | P/B | 3.03 | P/C | — |
| EV/EBITDA | -1.65 | EV/Sales | 134.81 | Quick Ratio | 3.59 |
| Current Ratio | 3.67 | Debt/Eq | 1.83 | LT Debt/Eq | — |
| EPS (ttm) | -0.69 | EPS next Y | -0.70 | EPS Growth | — |
| Revenue Growth | 60.90% | Earnings | 2026-05-07 | ROA | -38.47% |
| ROE | -71.45% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -32.21% | Profit Margin | 0.00% | Shs Outstand | 68.36M |
| Shs Float | 66.71M | Short Float | 27.40% | Short Ratio | 11.08 |
| Short Interest | — | 52W High | 4.56 | 52W Low | 1.48 |
| Beta | 1.37 | Avg Volume | 1.23M | Volume | 595.38K |
| Target Price | $7.75 | Recom | Strong_buy | Prev Close | $2.02 |
| Price | $2.01 | Change | -0.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.75
Mean price target
2. Current target
$2.01
Latest analyst target
3. DCF / Fair value
$-5.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.01
Low
$2.00
High
$12.00
Mean
$7.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | main | Piper Sandler | Overweight → Overweight | $6 |
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $19 |
| 2025-06-24 | init | Jefferies | — → Hold | $4 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-02-28 | main | HC Wainwright & Co. | Buy → Buy | $17 |
| 2024-12-13 | main | Piper Sandler | Overweight → Overweight | $10 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-09-06 | init | Craig-Hallum | — → Buy | $8 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-06 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-01 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2023-08-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-08 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2023-03-29 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-03-07 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-09-16 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2022-09-13 | main | Piper Sandler | — → Overweight | $5 |
- Hear Cardiff Oncology at three March healthcare investor conferences - Stock Titan hu, 26 Feb 2026 08
- Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat Wed, 25 Feb 2026 08
- Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance hu, 29 Jan 2026 08
- Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha ue, 27 Jan 2026 08
- Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses - simplywall.st hu, 20 Nov 2025 08
- Would You Still Hold Cardiff Oncology Stock If It Fell 30%? - Trefis Sat, 20 Dec 2025 08
- $CRDF stock is up 5% today. Here's what we see in our data. - Quiver Quantitative Fri, 01 Aug 2025 07
- Cardiff Oncology stock tumbles after Phase 2 trial data update - Investing.com Nigeria ue, 27 Jan 2026 08
- Wall Street Zen Upgrades Cardiff Oncology Stock Rating - National Today Fri, 06 Mar 2026 08
- Clinical roundup: Cardiff, VYNE and NewAmsterdam share trial updates across three disease areas - FirstWord Pharma Wed, 30 Jul 2025 07
- Cancer biotech Cardiff Oncology swaps leaders as key drug nears late-stage tests - Stock Titan ue, 27 Jan 2026 08
- Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance Wed, 10 Dec 2025 08
- Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat Wed, 04 Mar 2026 07
- Cardiff Oncology: Preparing For A Defining 2026 - Seeking Alpha Sat, 25 Oct 2025 07
- Colorectal trial: 72.2% response with Cardiff Oncology's onvansertib combo - Stock Titan ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 261 | — | — | ERLANDER MARK | Officer | — | 2020-01-02 00:00:00 | D |
| 1 | 1250 | — | — | ERLANDER MARK | Officer | — | 2020-01-01 00:00:00 | D |
| 2 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-10-01 00:00:00 | D |
| 3 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-07-01 00:00:00 | D |
| 4 | 1250 | — | — | ERLANDER MARK | Officer | — | 2019-04-01 00:00:00 | D |
| 5 | 1563 | — | — | ERLANDER MARK | Officer | — | 2019-01-02 00:00:00 | D |
| 6 | 7500 | — | — | ERLANDER MARK | Officer | — | 2019-01-01 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -48.06M | -48.25M | -45.01M | -39.67M |
| TotalUnusualItems | 285.00K | |||
| TotalUnusualItemsExcludingGoodwill | 285.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -45.85M | -45.43M | -41.44M | -38.70M |
| ReconciledDepreciation | 904.00K | 404.00K | 398.00K | 236.00K |
| EBITDA | -48.06M | -48.25M | -45.01M | -39.67M |
| EBIT | -48.96M | -48.65M | -45.41M | -39.90M |
| NetInterestIncome | 3.10M | 3.26M | 4.07M | 1.58M |
| InterestExpense | 0.00 | |||
| InterestIncome | 3.10M | 3.26M | 4.07M | 1.58M |
| NormalizedIncome | -45.85M | -45.43M | -41.44M | -38.70M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -45.85M | -45.43M | -41.44M | -38.70M |
| TotalExpenses | 49.55M | 49.33M | 45.90M | 40.29M |
| TotalOperatingIncomeAsReported | -48.96M | -48.65M | -45.41M | -39.90M |
| DilutedAverageShares | 66.84M | 47.65M | 44.68M | 43.60M |
| BasicAverageShares | 66.84M | 47.65M | 44.68M | 43.60M |
| DilutedEPS | -0.69 | -0.95 | -0.93 | -0.89 |
| BasicEPS | -0.69 | -0.95 | -0.93 | -0.89 |
| DilutedNIAvailtoComStockholders | -45.88M | -45.45M | -41.47M | -38.73M |
| NetIncomeCommonStockholders | -45.88M | -45.45M | -41.47M | -38.73M |
| PreferredStockDividends | 25.00K | 24.00K | 24.00K | 24.00K |
| NetIncome | -45.85M | -45.43M | -41.44M | -38.70M |
| NetIncomeIncludingNoncontrollingInterests | -45.85M | -45.43M | -41.44M | -38.70M |
| NetIncomeContinuousOperations | -45.85M | -45.43M | -41.44M | -38.70M |
| PretaxIncome | -45.85M | -45.43M | -41.44M | -38.70M |
| OtherIncomeExpense | 5.00K | -39.00K | -98.00K | -383.00K |
| OtherNonOperatingIncomeExpenses | 5.00K | -39.00K | -98.00K | -383.00K |
| GainOnSaleOfSecurity | 285.00K | |||
| NetNonOperatingInterestIncomeExpense | 3.10M | 3.26M | 4.07M | 1.58M |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 3.10M | 3.26M | 4.07M | 1.58M |
| OperatingIncome | -48.96M | -48.65M | -45.41M | -39.90M |
| OperatingExpense | 49.55M | 49.33M | 45.90M | 40.29M |
| ResearchAndDevelopment | 35.33M | 36.85M | 32.86M | 27.11M |
| SellingGeneralAndAdministration | 14.22M | 12.48M | 13.04M | 13.18M |
| GeneralAndAdministrativeExpense | 14.22M | 12.48M | 13.04M | 13.18M |
| OtherGandA | 6.93M | 6.10M | 6.28M | 6.83M |
| SalariesAndWages | 7.29M | 6.39M | 6.76M | 6.36M |
| TotalRevenue | 593.00K | 683.00K | 488.00K | 386.00K |
| OperatingRevenue | 593.00K | 683.00K | 488.00K | 386.00K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 68.31M | 66.52M | 44.68M | 44.68M |
| ShareIssued | 68.31M | 66.52M | 44.68M | 44.68M |
| TotalDebt | 832.00K | 1.52M | 2.15M | 2.71M |
| TangibleBookValue | 45.39M | 82.95M | 69.74M | 106.34M |
| InvestedCapital | 45.39M | 82.95M | 69.74M | 106.34M |
| WorkingCapital | 43.73M | 81.63M | 66.97M | 103.48M |
| NetTangibleAssets | 45.39M | 82.95M | 69.74M | 106.34M |
| CapitalLeaseObligations | 832.00K | 1.52M | 2.15M | 2.71M |
| CommonStockEquity | 45.39M | 82.95M | 69.74M | 106.34M |
| PreferredStockEquity | 1.00K | |||
| TotalCapitalization | 45.39M | 82.95M | 69.74M | 106.34M |
| TotalEquityGrossMinorityInterest | 45.39M | 82.95M | 69.74M | 106.34M |
| StockholdersEquity | 45.39M | 82.95M | 69.74M | 106.34M |
| OtherEquityInterest | -139.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 50.00K | 34.00K | -67.00K | -395.00K |
| OtherEquityAdjustments | 50.00K | 34.00K | -67.00K | -395.00K |
| RetainedEarnings | -430.03M | -384.18M | -339.54M | -298.10M |
| AdditionalPaidInCapital | 475.36M | 467.09M | 409.34M | 404.83M |
| CapitalStock | 7.00K | 7.00K | 4.00K | 4.00K |
| CommonStock | 7.00K | 7.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 16.50M | 14.24M | 11.90M | 9.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 102.00K | 813.00K | 1.46M | 2.04M |
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 102.00K | 813.00K | 1.46M | 2.04M |
| LongTermCapitalLeaseObligation | 102.00K | 813.00K | 1.46M | 2.04M |
| CurrentLiabilities | 16.39M | 13.43M | 10.44M | 7.81M |
| OtherCurrentLiabilities | 42.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 730.00K | 710.00K | 691.00K | 675.00K |
| CurrentCapitalLeaseObligation | 730.00K | 710.00K | 691.00K | 675.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.43M | 2.75M | 2.74M | 1.85M |
| PayablesAndAccruedExpenses | 13.23M | 9.97M | 7.01M | 5.28M |
| CurrentAccruedExpenses | 4.40M | 5.15M | 5.05M | 3.33M |
| Payables | 8.83M | 4.82M | 1.97M | 1.96M |
| OtherPayable | 744.00K | |||
| DividendsPayable | 0.00 | 414.00K | ||
| AccountsPayable | 8.09M | 4.82M | 1.97M | 1.96M |
| TotalAssets | 61.88M | 97.19M | 81.64M | 116.19M |
| TotalNonCurrentAssets | 1.76M | 2.14M | 4.22M | 4.91M |
| OtherNonCurrentAssets | 549.00K | 69.00K | 1.28M | 1.39M |
| NetPPE | 1.21M | 2.07M | 2.95M | 3.52M |
| AccumulatedDepreciation | -4.47M | -4.14M | -3.75M | -3.41M |
| GrossPPE | 5.67M | 6.20M | 6.70M | 6.93M |
| Leases | 2.57M | 2.57M | 2.57M | 2.56M |
| OtherProperties | 2.06M | 2.58M | 3.06M | 3.31M |
| MachineryFurnitureEquipment | 1.05M | 1.05M | 1.07M | 1.07M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 60.13M | 95.05M | 77.41M | 111.28M |
| OtherCurrentAssets | 1.64M | 2.54M | 2.30M | 5.25M |
| PrepaidAssets | 4.77M | |||
| Receivables | 182.00K | 773.00K | 288.00K | 771.00K |
| AccountsReceivable | 182.00K | 773.00K | 288.00K | 771.00K |
| CashCashEquivalentsAndShortTermInvestments | 58.30M | 91.75M | 74.82M | 105.27M |
| OtherShortTermInvestments | 40.83M | 40.28M | 53.17M | 88.92M |
| CashAndCashEquivalents | 17.47M | 51.47M | 21.66M | 16.35M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.97M | -37.77M | -31.47M | -34.83M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 53.41M | 0.00 | 0.00 |
| CapitalExpenditure | -44.00K | -80.00K | -582.00K | -1.01M |
| IncomeTaxPaidSupplementalData | 1.00K | 1.00K | 1.00K | 2.00K |
| EndCashPosition | 17.47M | 51.47M | 21.66M | 16.35M |
| BeginningCashPosition | 51.47M | 21.66M | 16.35M | 11.94M |
| ChangesInCash | -34.00M | 29.82M | 5.31M | 4.40M |
| FinancingCashFlow | 2.58M | 53.78M | 0.00 | 75.00K |
| CashFlowFromContinuingFinancingActivities | 2.58M | 53.78M | 0.00 | 75.00K |
| ProceedsFromStockOptionExercised | 2.58M | 373.00K | 0.00 | 75.00K |
| NetCommonStockIssuance | 0.00 | 53.41M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 53.41M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 1.34M | 13.73M | 36.20M | 38.15M |
| CashFlowFromContinuingInvestingActivities | 1.34M | 13.73M | 36.20M | 38.15M |
| NetOtherInvestingChanges | 114.00K | |||
| NetInvestmentPurchaseAndSale | 1.39M | 13.81M | 36.78M | 39.04M |
| SaleOfInvestment | 73.25M | 37.37M | 106.86M | 130.27M |
| PurchaseOfInvestment | -71.86M | -23.56M | -70.08M | -91.23M |
| CapitalExpenditureReported | -44.00K | -80.00K | -582.00K | -1.01M |
| OperatingCashFlow | -37.92M | -37.69M | -30.89M | -33.82M |
| CashFlowFromContinuingOperatingActivities | -37.92M | -37.69M | -30.89M | -33.82M |
| ChangeInWorkingCapital | 2.18M | 3.17M | 6.57M | -380.00K |
| ChangeInOtherCurrentLiabilities | -691.00K | -626.00K | -566.00K | -446.00K |
| ChangeInOtherCurrentAssets | -480.00K | 1.75M | 651.00K | -603.00K |
| ChangeInPayablesAndAccruedExpense | 2.20M | 2.98M | 2.83M | 1.35M |
| ChangeInPrepaidAssets | 557.00K | -452.00K | 3.17M | -443.00K |
| ChangeInReceivables | 591.00K | -484.00K | 483.00K | -236.00K |
| OtherNonCashItems | 139.00K | 2.03M | ||
| StockBasedCompensation | 5.69M | 4.76M | 4.51M | 4.26M |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -848.00K | -598.00K | -921.00K | 632.00K |
| DepreciationAmortizationDepletion | 904.00K | 404.00K | 398.00K | 236.00K |
| DepreciationAndAmortization | 904.00K | 404.00K | 398.00K | 236.00K |
| Depreciation | 904.00K | 404.00K | 398.00K | 236.00K |
| OperatingGainsLosses | 1.00K | -284.00K | ||
| GainLossOnInvestmentSecurities | -285.00K | |||
| NetIncomeFromContinuingOperations | -45.85M | -45.43M | -41.44M | -38.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRDF
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|